| Title |
Liquid biopsy-based DNA methylation biomarkers for breast cancer precision medicine / |
| Authors |
Sadzevičienė, Ieva ; Kaubrys, Danielius ; Jarmalaitė, Sonata |
| DOI |
10.1017/erm.2025.10008 |
| Full Text |
|
| Is Part of |
Expert reviews in molecular medicine.. Cambridge : Cambridge University Press. 2025, first published online, p. 1-35.. eISSN 1462-3994 |
| Keywords [eng] |
Breast cancer ; liquid biopsy ; cell-free DNA (cfDNA) ; DNA hypermethylation ; genome-wide methylation ; DNA methylation biomarkers |
| Abstract [eng] |
Current breast cancer (BC) diagnostics include detailed pathological and genetic analysis for biological subtype identification, however, throughout the course of the disease, new alterations determining the progression of the disease or resistance to treatment appear. The tests based on liquid biopsy allow minimally invasive real-time monitoring of tumour specific alteration during the entire disease treatment. Tumour-specific genetic material fragments occur in bodily fluids and cell-free nucleic acids are a convenient tool for analysing genetic and epigenetic changes in tumours. The evidence on the diagnostic and prognostic value of epigenetic biomarkers' is gradually increasing. Although up to date there is limited access to in vitro diagnostics (IVD) epigenetic liquid-biopsy-based tests for BC management, the data on the clinical potential of such tests and biomarkers is accumulating rapidly. In this review, we focused on research of cell-free DNA (cfDNA) methylation biomarkers in blood serum or plasma samples from BC patients. Our review systematizes data from genome-wide and targeted studies of DNA methylation changes in liquid biopsies from BC patients, aiming to highlight the most critical biomarkers suitable for early BC diagnosis, treatment personalization, and prognosis. |
| Published |
Cambridge : Cambridge University Press |
| Type |
Journal article |
| Language |
English |
| Publication date |
2025 |
| CC license |
|
